It's okay.
I was getting there in the sense that COVAX was always intended to try to protect those doses, recognizing that wealthier countries would be entering into bilateral deals. It was trying to protect that supply to provide doses for the most vulnerable frontline health care workers in developing countries.
Canada entered into bilateral deals because we also recognized back last summer that we didn't know which vaccines were going to be successful. Some of the deals we have are for the same vaccines that are part of COVAX. Some are for different ones. One that is the same is AstraZeneca. Another that is the same is Novavax. Moderna is not one of those, and Pfizer wasn't at the beginning either. Not knowing which one would be successful and knowing that our objective was to ensure that Canadians got access to vaccines, we have had a diversified portfolio.